Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinternmed.2010.132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 Testing Equity in New York City During the First 2 Years of the Pandemic: Demographic Analysis of Free Testing Data.
JMIR Public Health Surveill
March 2025
NYC Test & Treat Corps, The New York City Health + Hospitals Corporation, 50 Water St., New York, NY, 10004, United States, 1 212-788-3339, 1 212-788-3673.
Background: COVID-19 has caused over 46,000 deaths in New York City, with a disproportional impact on certain communities. As part of the COVID-19 response, the city has directly administered over 6 million COVID-19 tests (in addition to millions of indirectly administered tests not covered in this analysis) at no cost to individuals, resulting in nearly half a million positive results. Given that the prevalence of testing, throughout the pandemic, has tended to be higher in more affluent areas, these tests were targeted to areas with fewer resources.
View Article and Find Full Text PDFEpithelial-Myoepithelial Carcinoma of the Submandibular Gland Arising from Recurrent Pleomorphic Adenoma: A Rare Case Report.
Ear Nose Throat J
March 2025
ENT Department and Cervical Surgery Farhat Hached Hospital, Medicine University, Sousse, Tunisia.
A 36-year-old male with a history of smoking presented with recurrent right submandibular swelling. Initially diagnosed with pleomorphic adenoma, he underwent total submandibulectomy. After 2 years, he developed a recurrent submandibular mass.
View Article and Find Full Text PDFPretreatment Liquid Biopsy and Clinicopathologic Features in HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
JAMA Otolaryngol Head Neck Surg
March 2025
Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York.
Importance: Despite the favorable prognosis for HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), efforts to de-escalate treatment intensity, while maintaining low recurrence and mortality rates, have proven challenging. Identifying appropriate prognostic factors remains elusive; however, the association of pretreatment circulating tumor tissue viral-modified HPV (TTMV-HPV) DNA level with known characteristics of disease burden-clinical staging, characteristics of pretreatment imaging, and aggressive histopathologic features of surgical specimen-may offer insights that could shift treatment paradigms for HPV+ OPSCC.
Objective: To investigate the association of pretreatment TTMV-HPV DNA levels with clinical, radiologic, histopathologic, and outcome metrics in patients with HPV+ OPSCC.
Importance: Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.
Objective: To evaluate efficacy and safety of maintenance atezolizumab in patients with LA SCCHN at high risk of disease progression after multimodal definitive treatment.
Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas.
Ann Med
December 2025
Cancer Center, The First Hospital of Jilin University, Changchun, China.
Introduction: Since the Fourth edition of the WHO classification, PPGLs have been recognized for their metastatic potential, though no clear features can accurately predict this behavior. The prognostic value of Ki-67 in assessing the risk of progression, relapse, or metastasis in PPGLs remains debated.
Methods: This cohort study included 501 patients diagnosed with PPGLs at the First Hospital of Jilin University between 2000 and 2022, with clinical data, treatment details, pathological indicators, and germline gene test results collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!